EN DE

Fidia S.p.A (FDA) Fair Value & Analysis

Industrials · IT · Market cap €9.7M

FS Fidia S.p.A FDA · MI
Price€0.0084
Fair Value€0.0077
Upside-8.3%
Quality42/100
Watch Fidia S.p.A for free, get notified when fair value or trend changes. Watch for free
Expensive Growth
Thin margins · 3.2% net margin
Low debt · negative free cash flow
Mixed vs. peers (6/12)
Narrow moat 31/100
Evidence: Medium Range €0.0077 – €0.0085 Share as image

Fair value as of: Jul 31, 2026

From 8 valuation models · updated 10 days ago

Share price −10.6% over the past month.

Below-average quality, currently priced close to our fair value.

What matters now

  • The price sits close to our fair value, market and models broadly agree here, little valuation tension.
  • The models converge in a tight band (€0.0077 to €0.0085), unusually little disagreement for a valuation.
Share this valuation: 𝕏 WhatsApp

Price vs Fair Value (5 years)

€263.00 €0.0034 Fair Value €0.0077 May 2021 Aug 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 31, 2026.

How to read this chart

60‑month range €0.0034 – €263.00 · fair‑value band €0.0077 – €0.0085 · the €0.0084 price screens above the €0.0077 fair value. Dashed = 300-day average. As of Jul 31, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Fidia S.p.A (FDA) currently trades at €0.0084, while our model-based Fair Value estimate is €0.0077, implying the stock looks roughly 8.3% fairly valued today. The Quality Score stands at 42/100 (below-average quality), in the Industrials sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: medium).

Over the trailing twelve months, Fidia S.p.A generated revenue of €32.4M at a net margin of 3.2%. Revenue grew 107.5% year over year. It earns a return on equity of 18.3%. Net debt stands at €1.0M. Fundamentals as of Jul 31, 2026

Our scenario range runs from €0.0077 (bear case) to €0.0085 (bull case); at €0.0084, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. For context, the median of 10 Industrials peers we cover trades at -48% fair-value upside, at -8%, FDA screens cheaper than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Model Bear Bear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull Bull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence
Highest evidence
Residual Income €0.0100 €0.0100 €0.0100 76
Growth-Adj P/E €0.0100 €0.0100 €0.0200 68
P/E Multiple €0.0100 €0.0200 €0.0200 63
All 8 models by family
DCF Models
Owner Earnings €0.0100 €0.0100 €0.0100 31
Earnings-Based
Graham-Dodd €0.0100 €0.0100 €0.0100 54
Multiples
P/E Multiple €0.0100 €0.0200 €0.0200 63
P/S Multiple €0.0100 €0.0100 €0.0200 58
P/B Multiple €0.0100 €0.0100 €0.0200 55
Asset-Based
NCAV (Graham) €0.0100 50
Economic Profit
Residual Income €0.0100 €0.0100 €0.0100 76
Growth Earnings
Growth-Adj P/E €0.0100 €0.0100 €0.0200 68

Widest divergence: DCF Models (€0.0100) versus DCF Models (€0.0100). Highest evidence: Residual Income (76).

Notify me when FDA reaches fair value

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.

Key figures & financial health

Revenue (TTM) €32.4M
Revenue growth (YoY) +108%
Net margin 3.2%
Return on equity 18.3%
Free cash flow −€4.4M FY2025
Operating margin 2.4%
More key figures
EPS growth (YoY) -78.3%
Net debt €1.0M FY2023

Figures from reported company fundamentals · as of Jul 31, 2026. TTM = trailing twelve months.

Quality Score breakdown

Overall quality 42/100

Of which business quality 42 · Market factors (momentum, volatility) 30

Profitability 61
Margins and returns on capital today
Quality Growth 80
Are margins and returns improving?
Cashflow 0
Earnings quality: real cash, not paper profit
Fin. Strength 47
Balance sheet, leverage, solvency risk
Investment 79
Disciplined investing over empire-building
Low Volatility 50
Calm price path (market factor)
Momentum 33
Price trend over the last 3–12 months (market factor)
52W Momentum 1
Distance to the 52-week high (market factor)
Net Issuance 0
Buybacks instead of dilution

Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.

About the company

Fidia S.p.A., together with its subsidiaries, designs, manufactures, and sells high speed milling systems, numerical controls, milling heads, and software systems.

Full company description

Fidia S.p.A., together with its subsidiaries, designs, manufactures, and sells high speed milling systems, numerical controls, milling heads, and software systems. The company offers HMS, a device for measuring and compensating geometric error on continuous or indexed bi-rotary heads and roto-tilting tables; TMSC, a device to measure length and diameter of the tool, as well as to check the shape; pushbutton panels; XPower digital drives for axis and spindle movement; and I/O Line input/output modules. It also provides software solutions include ViMill, an anti-collision solution; Machine Monitor, a software to monitor NC variables and parameters; Velocity 6, a solution for axes control to enhance the performances of the machine; HiMill, a CAM software for the machining of dies, models, and aeronautical components; Isograph solution, a user interface; and procedure-PRX, a solution for customized automation. It serves automotive, aerospace, and power generation industries in Italy, Europe, Asia, North and South America, and internationally. The company was founded in 1974 and is headquartered in San Mauro Torinese, Italy.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

Fidia S.p.A reported revenue of €31.1M in FY2025 versus €23.8M in FY2021, a compound +6.9%/yr. Reported net income was €1.0M in FY2025.

Growth Quality 49/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Latest Revenue (FY 2025)
€31.1M
Latest YoY
+77.8%
Avg. growth/yr (3Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+8.5%
Avg. growth/yr (5Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+7.9%
Avg. growth/yr (25Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
−27.0%
Revenue +6.9%/yr
FY21 €23.8M
FY22 €24.4M
FY23 €28.6M
FY24 €17.5M
FY25 €31.1M
Net income
FY21 −€3.5M
FY22 €6.0M
FY23 −€1.3M
FY24 −€9.3M
FY25 €1.0M

Watch FDA: get an alert when its fair value changes →

Share or link this analysis
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cite: Fair Value Calculator (2026). "Fidia S.p.A Fair Value". https://www.fairvalue-calculator.com/stock/FDA

Peer Group

Specialty Industrial Machinery · 808 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Quality Score 42 · Bottom 25%
Fair Value upside −8% · Above median
Return on equity (TTM) 18% · Top 25%
Return on assets -2% · Bottom 25%
Net margin (TTM) 3% · Below median
Operating margin (TTM) 2% · Below median
Revenue growth 108% · Top 25%
Debt / equity 0.18× · Higher than median

Valuation Multiples vs Specialty Industrial Machinery median · lower = cheaper

P/B 1.40× · Cheaper than median
P/S (TTM) 0.35× · Cheaper than 75% of peers
EV/EBITDA 27.8× · Pricier than 75% of peers
PEG 1.06× · Cheaper than median

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUE 22 · sector 0
FUTURE 100 · sector 23
PAST 73 · sector 28
HEALTH 91 · sector 96
DIVIDEND 0 · sector 24

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Specialty Industrial Machinery stocks, each showing price versus our Fair Value estimate (as of Jul 31, 2026).

Stock Price Fair Value vs Fair Value
GE Vernova Inc 1GEV €887.60 €186.93 -79%
1SIE 1SIE €273.20 €91.93 -66%
SMNS SMNS C$31.76 C$22.68 -29%
Eaton Corporation ETN $407.28 $171.92 -58%
Atlas Copco AB ATCOA kr 195.15 kr 112.59 -42%
Sandvik AB SAND kr 384.10 kr 193.01 -50%
Doosan Enerbility Co 034020 76,400 KRW 7,938 KRW -90%
Vestas Wind Systems A/S VWS kr 178.10 kr 124.54 -30%
Zhejiang Sanhua Intelligent Controls Co 002050 ¥43.20 ¥22.68 -48%
NARI Technology Co 600406 ¥22.19 ¥18.71 -16%

Compare Fidia S.p.A with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Explore undervalued stocks

More undervalued Industrials stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Frequently asked questions

Is Fidia S.p.A (FDA) overvalued or undervalued?
As of Jul 31, 2026, our model estimates a fair value of €0.0077 versus a price of €0.0084, about −8% (fairly valued).
What is the fair value of FDA?
Our model-based fair value for Fidia S.p.A is €0.0077 (as of Jul 31, 2026), built from audited fundamentals. The current price is €0.0084.
What is the quality score of FDA?
Fidia S.p.A has a Quality Score of 42/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the revenue of Fidia S.p.A (FDA)?
Fidia S.p.A reported trailing-twelve-month revenue of about €32.4M (latest available figure, as of Jul 31, 2026).
What is the net profit margin of FDA?
The net profit margin of Fidia S.p.A is about 3.2%, meaning it keeps roughly 3.2% of revenue as net income. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.

14 days Pro free · no card

Track Fidia S.p.A and try Pro for 14 days

One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.

Zero risk: nothing is ever charged. After 14 days you decide whether to stay.